Low-dose chemotherapy, including gemcitabine [276] and 5-fluorouracil [277], has proven effective in depleting MDSC populations in tumor bearers, and tyrosine kinase inhibitors (including Sunitinib [278]) have successfully eliminated MDSCs in cancer patients by blocking VEGF, STAT3, and c-KIT signaling. This evidence concerns the gene VEGFA and neoplasm.